ABT-263 (Navitoclax) 化学構造
分子量: 974.61

高品質保証

文献中の引用(35)

カスタマーフィードバック(13)

Quality Control & MSDS

製品説明

  • Compare Bcl-2 Inhibitors
    Bcl-2製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 ABT-263(Navitoclax)は、 Bcl-xLBcl-2Bcl-w の強力な阻害剤で、Kiがそれぞれ ≤ 0.5 nM、≤1 nM 、≤ 1 nMです。
ターゲット

Bcl-xL

Bcl-2

Bcl-w

IC50

≤ 0.5 nM (Ki)

≤1 nM (Ki)

≤ 1 nM (Ki)[1]

In vitro試験 ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
EoL-1-cell MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HMWGlEPTB;MD6wNFY3QSEQvF2= MlXjV2FPT0WU
MV-4-11 M1jGT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4W5cmlEPTB;MD6wNVU5PiEQvF2= MUfTRW5ITVJ?
NKM-1 M1z0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLkTWM2OD1yLkCxOlk6KM7:TR?= NETU[oxUSU6JRWK=
ML-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH2VnFKSzVyPUCuNFE6QDNizszN MWXTRW5ITVJ?
BV-173 MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwMEKzNVQh|ryP MUfTRW5ITVJ?
RS4-11 NX35[W1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTScFFKSzVyPUCuNFI2QDdizszN MUfTRW5ITVJ?
HL-60 M3\V[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjGTmNKSzVyPUCuNFI6ODhizszN M334VnNCVkeHUh?=
KY821 MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK2SI1KSzVyPUCuNFI6PzVizszN MoewV2FPT0WU
ECC10 NFnKTmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwMEO3PVIh|ryP NVK5eGd5W0GQR1XS
NCI-H720 NGLiSXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwMESwNVEh|ryP NYPlSVFTW0GQR1XS
QIMR-WIL MoLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoWwTWM2OD1yLkC0Nlg4KM7:TR?= Moi0V2FPT0WU
KG-1 NEnUSGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jK[mlEPTB;MD6wOFQ5PiEQvF2= MVPTRW5ITVJ?
TGW MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwMES2N|Mh|ryP MkDtV2FPT0WU
ATN-1 NEHjTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjDd5ZKSzVyPUCuNFQ4OzNizszN NITWNmxUSU6JRWK=
RH-18 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwME[wOFgh|ryP Moq2V2FPT0WU
EW-18 Mnq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwME[4OFEh|ryP NVPaeo5NW0GQR1XS
NB17 NVG5fm9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLJelRKSzVyPUCuNFcyOjRizszN MWfTRW5ITVJ?
SK-NEP-1 M2rGZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvjOYYzUUN3ME2wMlA4OjF|IN88US=> NXy3OFRMW0GQR1XS
P12-ICHIKAWA MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUSyXWc2UUN3ME2wMlA4Pzd6IN88US=> NVnqO216W0GQR1XS
KARPAS-45 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXofZJFUUN3ME2wMlA4QDF3IN88US=> M4L5[XNCVkeHUh?=
EW-3 NX:wR4lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PiNmlEPTB;MD6wPFA2OyEQvF2= MVnTRW5ITVJ?
NB13 NYPKe2VPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT3eZNKSzVyPUCuNFgzODNizszN M3vmWXNCVkeHUh?=
NCI-H209 NFXLSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jydGlEPTB;MD6wPFcxPCEQvF2= MYXTRW5ITVJ?
NCI-H1092 Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwMUCyO|Uh|ryP MVfTRW5ITVJ?
NH-12 NYTQNHhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXUXmxKSzVyPUCuNVA4PDRizszN M12zXHNCVkeHUh?=
697 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwMUC4N|kh|ryP NIPl[3FUSU6JRWK=
KE-37 NI\JXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LuZmlEPTB;MD6xNVM4KM7:TR?= NV;sUo9DW0GQR1XS
MOLT-4 NGrP[WpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTT[oJKSzVyPUCuNVUyPjlizszN MXHTRW5ITVJ?
CHP-134 M4fBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMU[zNFYh|ryP M2LLR3NCVkeHUh?=
D-283MED M{TYO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rifGlEPTB;MD6xO|Y5PiEQvF2= M1zuOXNCVkeHUh?=
LU-135 MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIe5bYpKSzVyPUCuNVg2PTJizszN MXzTRW5ITVJ?
LU-134-A MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\oeFZmUUN3ME2wMlE5PjdzIN88US=> MVXTRW5ITVJ?
EM-2 M1HPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYL6U3RoUUN3ME2wMlE6QTF6IN88US=> M17QU3NCVkeHUh?=
LU-139 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3Scog{UUN3ME2wMlIxPDl6IN88US=> MlrGV2FPT0WU
ALL-PO NHvPeFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjSWoxHUUN3ME2wMlIyQTh6IN88US=> M3vBVnNCVkeHUh?=
NB12 NX\IV4xVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17XSWlEPTB;MD6yN|EyPSEQvF2= MYrTRW5ITVJ?
KP-N-YN M1\uTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrmTWM2OD1yLkKzOVc{KM7:TR?= NXe0WWVRW0GQR1XS
BEN NV;aSYNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjlZXRKSzVyPUCuNlM6PjhizszN MVLTRW5ITVJ?
HCC1569 MmjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMkWxNFYh|ryP MXHTRW5ITVJ?
HuO9 M3e5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwMk[3NVUh|ryP NU[1eo9MW0GQR1XS
WM-115 M1WxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;RNWlEPTB;MD6yO|c{QCEQvF2= MVnTRW5ITVJ?
CCRF-CEM NXzMc4lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwM{O1Nlkh|ryP NX\rVoFTW0GQR1XS
IST-SL1 M125Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHKTWM2OD1yLkO1N|Q{KM7:TR?= NXTDeFlRW0GQR1XS
BE-13 Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwM{[0OVkh|ryP NHHaTmJUSU6JRWK=
COR-L88 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT6b4hKSzVyPUCuN|Y2PCEQvF2= M3nsRnNCVkeHUh?=
DOHH-2 NV\TbI5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\veGlEPTB;MD60NVAzOyEQvF2= MnrLV2FPT0WU
A704 NInmWllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rjTGlEPTB;MD60NlY4KM7:TR?= NUK0SXJqW0GQR1XS
KNS-81-FD NFTpUGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwNESwNVch|ryP MV\TRW5ITVJ?
RPMI-8226 NXLVWG5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPHdmh5UUN3ME2wMlQ2PjV{IN88US=> NUXZWWY{W0GQR1XS
TGBC24TKB MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwNEW3O|gh|ryP MWrTRW5ITVJ?
NCI-H1304 NWfpd2RYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v4emlEPTB;MD60OlE2PyEQvF2= NUPuVmFuW0GQR1XS
MOLT-13 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjw[4JKSzVyPUCuOFY3OTNizszN M2DL[XNCVkeHUh?=
EW-22 M3fscGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC5NFZDUUN3ME2wMlQ3PjdzIN88US=> NEjldZlUSU6JRWK=
MS-1 M4DqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVe3T|dvUUN3ME2wMlQ3QTN|IN88US=> MlPBV2FPT0WU
RMG-I MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPJTWM2OD1yLkS5OFY1KM7:TR?= MnXmV2FPT0WU
NTERA-S-cl-D1 Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoftTWM2OD1yLkWwNFE6KM7:TR?= MkftV2FPT0WU
NCI-H1048 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4r4VGlEPTB;MD61NFk2OyEQvF2= NVTrVnU1W0GQR1XS
SW1417 NGHPT2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3RTWM2OD1yLkW1OFM5KM7:TR?= MmHaV2FPT0WU
DB M3fSXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwNUewPEDPxE1? NXXHVG5tW0GQR1XS
MEG-01 Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HDT2lEPTB;MD61PFMzKM7:TR?= NHS5PFhUSU6JRWK=
EW-13 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwNUizOFEh|ryP NI\wZ4NUSU6JRWK=
LAMA-84 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwNUmyNFch|ryP MWfTRW5ITVJ?
J-RT3-T3-5 NYnIfGVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fqTWlEPTB;MD62NFgxQCEQvF2= MlL1V2FPT0WU
MOLT-16 M1nwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwNkWyOlQh|ryP Mn7DV2FPT0WU
DU-4475 M{XjWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnzZoloUUN3ME2wMlY2PDJ5IN88US=> NIHnXGJUSU6JRWK=
HAL-01 MnvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrWTWM2OD1yLkeyOVQ6KM7:TR?= NUPCc4FOW0GQR1XS
RD NGrX[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTJTWM2OD1yLke1PFk6KM7:TR?= NVHMW2V{W0GQR1XS
OAW-28 NXTPdFk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\kSmtbUUN3ME2wMlc5OzdizszN M2nOS3NCVkeHUh?=
HCC38 NWqyd2dGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwOECxPUDPxE1? NGfFWGRUSU6JRWK=
NMC-G1 M{P6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUT3VVk5UUN3ME2wMlgyOTJzIN88US=> NWDuV2dWW0GQR1XS
EW-16 M3HBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vOW2lEPTB;MD64NVMzQCEQvF2= MYTTRW5ITVJ?
DU-145 NHfvN3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M162NWlEPTB;MD64PVkzOyEQvF2= NGnHeXFUSU6JRWK=
HPAF-II NWTqVmdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HJe2lEPTB;MD65NlYzQCEQvF2= MVzTRW5ITVJ?
A427 NIG4SXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LFUmlEPTB;MD65N|AzOiEQvF2= M3v3S3NCVkeHUh?=
PA-1 MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwOUW2OFIh|ryP NXHGOlB[W0GQR1XS
OAW-42 NUH5WY5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwOU[xOFYh|ryP M4npVXNCVkeHUh?=
L-428 NWDDN5hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3M[pVkUUN3ME2xMlAyOjVizszN MmHPV2FPT0WU
COLO-824 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXWTWM2OD1zLkCxO|A5KM7:TR?= NFfqeZpUSU6JRWK=
P30-OHK NFqydFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC1U|ZEUUN3ME2xMlA1Pjh6IN88US=> NFfONm9USU6JRWK=
NCI-H2170 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvwTWM2OD1zLkC2NlMh|ryP NWfUZXU4W0GQR1XS
HCC2998 M3HzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLQWZA5UUN3ME2xMlA4OTN3IN88US=> NX3FSGVWW0GQR1XS
NB14 NF7h[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHNc4c4UUN3ME2xMlE{PzR6IN88US=> NWHiSlhSW0GQR1XS
TGBC1TKB Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\hcW06UUN3ME2xMlE1OTV{IN88US=> M4PFXXNCVkeHUh?=
KP-N-YS Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTFwMU[yN|Yh|ryP Mn\yV2FPT0WU
CAL-120 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTFwMU[0Nlkh|ryP M1e0fXNCVkeHUh?=
SBC-1 NGHZcG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:wbVdKSzVyPUGuNVkxPTNizszN NUHje5RXW0GQR1XS
C32 M3fUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrSS5VKSzVyPUGuNVkxQDhizszN NVz0W4NiW0GQR1XS
HCC2157 NGPxTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTFwMUm0PVQh|ryP NFnNdVBUSU6JRWK=
COLO-792 NYrRXmJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37Lb2lEPTB;MT6yNFA4OSEQvF2= MWfTRW5ITVJ?
ES7 M2\0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jifGlEPTB;MT6yO|k2OSEQvF2= NGjGOotUSU6JRWK=
HEL MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\IUmlEPTB;MT6zNVAzQSEQvF2= NIruWJBUSU6JRWK=
ES4 NEjKWG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\STWM2OD1zLkO0PVk5KM7:TR?= M3;4OnNCVkeHUh?=
NCI-SNU-1 NFX2WZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTFwM{[1OVUh|ryP MkfKV2FPT0WU
MDA-MB-415 MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnhcJByUUN3ME2xMlM5QDVizszN MUjTRW5ITVJ?
NCI-H2342 MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq2N4FuUUN3ME2xMlQxOjZ7IN88US=> NIe3fHBUSU6JRWK=
NB69 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXaT484UUN3ME2xMlQ3OjdzIN88US=> NELsNotUSU6JRWK=
D-247MG MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFwNUGxNlIh|ryP NH;IRmpUSU6JRWK=
SCC-4 M1jwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLMeIRsUUN3ME2xMlU6QDh5IN88US=> MnXVV2FPT0WU
HuH-7 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHafYZbUUN3ME2xMlY4Ojl|IN88US=> MUDTRW5ITVJ?
A388 NFnNTHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDWTWM2OD1zLk[4O|I1KM7:TR?= MmDJV2FPT0WU
Calu-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv1WG5OUUN3ME2xMlcxPjl5IN88US=> MVHTRW5ITVJ?
NCI-H1648 NHXDXm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFwN{G0NVgh|ryP Ml\6V2FPT0WU
NCI-H2052 NFvUVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnQfG9KSzVyPUGuO|IzODFizszN M4PXW3NCVkeHUh?=
Ramos-2G6-4C10 M3\MWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHRb4lOUUN3ME2xMlc{PjV4IN88US=> MV;TRW5ITVJ?
DEL M2DjNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHDXlBKSzVyPUGuO|Q3QTJizszN M1PrSnNCVkeHUh?=
SNU-423 MnTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUX3WWl2UUN3ME2xMlc5OTV5IN88US=> M4XMdnNCVkeHUh?=
COR-L23 MljpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUH1TpVxUUN3ME2xMlc6QDd2IN88US=> NIfEOXpUSU6JRWK=
OMC-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoniTWM2OD1zLki2NFE3KM7:TR?= MYnTRW5ITVJ?
EW-11 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnoTWM2OD1zLkm1OlU4KM7:TR?= M3;FbHNCVkeHUh?=
HSC-3 M2DzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPQTWM2OD1zLkm2N|Y2KM7:TR?= MojxV2FPT0WU
MLMA M{HzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLpTWM2OD1zLkm2Olc4KM7:TR?= NFP2U3ZUSU6JRWK=
RCM-1 NGfUOI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\qTWM2OD1{LkCwN|k6KM7:TR?= MnnnV2FPT0WU
MFE-280 MljWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:4TWM2OD1{LkCyPFQ5KM7:TR?= MV;TRW5ITVJ?
ES8 MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLxfI1KSzVyPUKuNlU1PzFizszN MVjTRW5ITVJ?
TE-11 M323VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrPb3lKSzVyPUKuNlk1PzNizszN MXTTRW5ITVJ?
HuO-3N1 M{nNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLYeYZvUUN3ME2yMlQ5PzhizszN NH2zNXJUSU6JRWK=
MHH-NB-11 NFPw[GVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vI[mlEPTB;Mj61NVE2QCEQvF2= MnLNV2FPT0WU
TGBC11TKB NYKz[Fh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFKyXlRKSzVyPUKuOVc3QDFizszN NF\pWpFUSU6JRWK=
HOP-92 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37QZWlEPTB;Mj61PFc1OyEQvF2= MWnTRW5ITVJ?
IGR-1 NFn4N4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfZRldlUUN3ME2yMlYzODN3IN88US=> NF7Sb4RUSU6JRWK=
GOTO NEW5NGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEn1VnVKSzVyPUKuOlU{PzdizszN MYXTRW5ITVJ?
NCI-H1650 M2LvTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLGXVhKSzVyPUKuO|IzOTVizszN NXzXXpNnW0GQR1XS
NCI-H1581 NFftNWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJwN{m2PFEh|ryP NHzhNnpUSU6JRWK=
NCI-H2405 NVTBV|Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjZTWM2OD1{LkiyO|gzKM7:TR?= NXm1elF3W0GQR1XS
U-118-MG MkSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGCz[YFKSzVyPUKuPVY1QTFizszN M2q2enNCVkeHUh?=
DoTc2-4510 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvadFRKSzVyPUOuNFE1OTdizszN MnXGV2FPT0WU
NCI-H596 M360RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7oepptUUN3ME2zMlA1QTl5IN88US=> Mmq3V2FPT0WU
MPP-89 NIXNboxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO3V29KSzVyPUOuNFU3PjZizszN MWDTRW5ITVJ?
GCIY NIXNT3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3S4c2lEPTB;Mz6yNFQ6OSEQvF2= MV;TRW5ITVJ?
SW626 M3y4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\tTWM2OD1|LkK0OVQ{KM7:TR?= NGXmVpNUSU6JRWK=
OCI-AML2 M2W1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLPSHBKSzVyPUOuN|EzPzJizszN M1ruU3NCVkeHUh?=
NBsusSR Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTh[mJKSzVyPUOuN|Q6OzhizszN MVzTRW5ITVJ?
AN3-CA MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIruOnlKSzVyPUOuOFQzOzhizszN MojLV2FPT0WU
EFM-19 NEW2SFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrDZZRKSzVyPUOuOFg{OzlizszN NXvqZ21ZW0GQR1XS
RVH-421 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWW1OppYUUN3ME2zMlU3QDd5IN88US=> MUHTRW5ITVJ?
5637 NVvKSpdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzjNXpKSzVyPUOuOlEyODNizszN NV7YR3Z4W0GQR1XS
PANC-08-13 M3:yemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL0TWM2OD1|Lk[zOFczKM7:TR?= MorjV2FPT0WU
H9 NFm3ToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTNwNkexOFQh|ryP MWjTRW5ITVJ?
KARPAS-299 M4TxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mli3TWM2OD1|Lk[3N|YyKM7:TR?= M1nDfXNCVkeHUh?=
TE-5 M2rzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37VdGlEPTB;Mz63NFcxQSEQvF2= M4TUb3NCVkeHUh?=
NOS-1 NUfHWZI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkG5TWM2OD1|Lke5PFM1KM7:TR?= MVrTRW5ITVJ?
HH MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LzWmlEPTB;Mz64N|g3QCEQvF2= M2DiW3NCVkeHUh?=
769-P NIrOb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTNwOEm1NUDPxE1? NHvGcWpUSU6JRWK=
CHP-212 NIfMd|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTNwOUK1OFkh|ryP NIm4N25USU6JRWK=
NCI-H82 M1LuU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjXU4VZUUN3ME2zMlk2QTN4IN88US=> NWOxRYN7W0GQR1XS
Mo-T MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTRwMESzNVIh|ryP M{HITHNCVkeHUh?=
BB65-RCC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTRwMESzPVkh|ryP NXXq[2pXW0GQR1XS
SW1990 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\1eHpKSzVyPUSuNFU6ODhizszN NF;K[VZUSU6JRWK=
LK-2 NWPEXGVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1n1WmlEPTB;ND6xNVI6OyEQvF2= M3nDR3NCVkeHUh?=
ES5 NULRdG1QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLRfWJKSzVyPUSuNVM6QDVizszN NH;MToJUSU6JRWK=
JVM-3 NXjuTYZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTRwMUiyNlIh|ryP NUXaOJl4W0GQR1XS
RPMI-7951 NXq3cYtxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnyxTWM2OD12LkKyOFE{KM7:TR?= MWHTRW5ITVJ?
Calu-6 MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTRwMke4PFEh|ryP NEXRRVRUSU6JRWK=
LC-2-ad NEDGZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm4TWM2OD12LkK5OVY5KM7:TR?= MWLTRW5ITVJ?
SW954 NECycmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVy4cVFzUUN3ME20MlI6PjZizszN M3rqcXNCVkeHUh?=
H-EMC-SS MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi3cmdKSzVyPUSuN|E5OzFizszN MV;TRW5ITVJ?
ES3 NGrmeG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrBcY9lUUN3ME20MlM2PDRzIN88US=> NVPvfJFEW0GQR1XS
no-11 MkWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[1TWM2OD12LkO1OVU1KM7:TR?= MVfTRW5ITVJ?
LAN-6 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;BTWM2OD12LkS1NVg6KM7:TR?= MUjTRW5ITVJ?
FTC-133 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPyTWM2OD12LkWzPVUh|ryP MYDTRW5ITVJ?
8505C NUXNRoI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\pUW1XUUN3ME20MlU1OjNizszN M2DqZXNCVkeHUh?=
SW620 M1\WNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTRwNUewOVch|ryP NHnjNYtUSU6JRWK=
BCPAP NV:3S2lxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\ZSWlEPTB;ND62N|Q5OSEQvF2= MX;TRW5ITVJ?
SK-LU-1 M{exWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILrNG5KSzVyPUSuOlYxQDlizszN MlrBV2FPT0WU
NCI-H1623 NEfyZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjRSZFKSzVyPUSuO|AzOjhizszN Mki3V2FPT0WU
C2BBe1 M4WyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjKPYJKSzVyPUSuO|QxODhizszN MUjTRW5ITVJ?
GP5d NHX2V2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjxe5VKSzVyPUSuO|g{QDhizszN MVPTRW5ITVJ?
NB6 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jRfWlEPTB;ND64OlIxPCEQvF2= MUTTRW5ITVJ?
MDA-MB-157 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfoTWM2OD12Lki4O|Yh|ryP MofvV2FPT0WU
UMC-11 NEHXR3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXXellQUUN3ME20Mlg5QTZ2IN88US=> Mo[3V2FPT0WU
HCC1419 Ml73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTRwOUCwOlMh|ryP NWPYdHlNW0GQR1XS
NCI-H2029 MmHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTRwOUSxPFUh|ryP MVXTRW5ITVJ?
LXF-289 NYrlOGc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\v[45KSzVyPUWuNFM4OTlizszN M1GwVHNCVkeHUh?=
KINGS-1 NYm3fZZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TCb2lEPTB;NT6wO|c1PCEQvF2= MYDTRW5ITVJ?
HD-MY-Z Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTYenRWUUN3ME21MlI{QTZ7IN88US=> NHXGfIpUSU6JRWK=
ESS-1 M{nuOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofWTWM2OD13LkK1OVk4KM7:TR?= MVHTRW5ITVJ?
GI-1 M3mz[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3BNppKSzVyPUWuNlc6OjZizszN M1i3SHNCVkeHUh?=
RPMI-2650 NGDvPGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvscGZyUUN3ME21MlM3OTZizszN NICx[JBUSU6JRWK=
IA-LM NInVbo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTVwM{m4O|Eh|ryP NVzUW3U1W0GQR1XS
KP-4 NYf6RWxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXU[JJKSzVyPUWuOFY{OzRizszN NFW1blFUSU6JRWK=
G-402 NUTQUVVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TZVWlEPTB;NT61NVg3PSEQvF2= MXHTRW5ITVJ?
OS-RC-2 NH7mUGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfUU4hKSzVyPUWuOVI3ODRizszN NHSxeItUSU6JRWK=
NCI-H1155 NVnFRWpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3KwO2lEPTB;NT61OFk2PSEQvF2= MojSV2FPT0WU
OE19 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTVwNki2NlQh|ryP NH[zenJUSU6JRWK=
U-2-OS MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTVwOEmwNVMh|ryP MVrTRW5ITVJ?
SCC-15 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTRTWM2OD13LkmzOlYzKM7:TR?= NIjvWotUSU6JRWK=
NCI-H630 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnwPVlLUUN3ME21Mlk6PDB2IN88US=> NUXDWotxW0GQR1XS
PFSK-1 NWTWV4ltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fqOmlEPTB;Nj6wOVI2QSEQvF2= M4DMdXNCVkeHUh?=
NCI-H1770 NGTFVm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTZwMkC4O|Qh|ryP NWK3S4Y1W0GQR1XS
SK-MEL-3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTZwNEK5NVUh|ryP MX;TRW5ITVJ?
LB1047-RCC NI[5UlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3jdoZCUUN3ME22MlQ4PjJ3IN88US=> MUjTRW5ITVJ?
NCI-H446 NHTNXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nDemlEPTB;Nj62NlkzPSEQvF2= MnPOV2FPT0WU
SW780 NHyxNYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3n4[2lEPTB;Nj63NFE5PSEQvF2= NXfsUGY5W0GQR1XS
NEC8 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{ewOWlEPTB;Nj63OlY{KM7:TR?= MXrTRW5ITVJ?
NOMO-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7XbZRKSzVyPU[uO|gyOTFizszN NHrMT2hUSU6JRWK=
COLO-668 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVq0S4w5UUN3ME22Mlg1Ozh5IN88US=> M3HKXnNCVkeHUh?=
MC116 MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTZwOUO4PVch|ryP NEDsRYlUSU6JRWK=
HCC1937 NV;NNZIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrzOm1KSzVyPU[uPVkzPTFizszN NGjpeWlUSU6JRWK=
NCI-N87 NUHiU3hZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTdwMUmyPVMh|ryP NWPkPHBQW0GQR1XS
COLO-320-HSR MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PFc2lEPTB;Nz6yNlc{QCEQvF2= M1[3[nNCVkeHUh?=
HCC1806 MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnWNnJEUUN3ME23MlI3ODR2IN88US=> NHPPbWtUSU6JRWK=
OVCAR-3 MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\PTWM2OD15LkOzNFM5KM7:TR?= NX;o[|lKW0GQR1XS
NUGC-3 MmLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:4eGlEPTB;Nz6zPVY6PCEQvF2= NVz4S2MzW0GQR1XS
SW1783 MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTdwNEOxO|Uh|ryP Ml7hV2FPT0WU
GCT MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTdwNU[5NFYh|ryP M{THc3NCVkeHUh?=
NCI-H2126 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz6TWM2OD15LkezOlI2KM7:TR?= MUjTRW5ITVJ?
MEL-HO M17Qdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfoVlBKSzVyPUeuO|cxPTRizszN MoTMV2FPT0WU
CAPAN-1 NW\qT2ljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzRWoNnUUN3ME23Mlc4OzV5IN88US=> M2W2PXNCVkeHUh?=
SW756 M2jJWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTdwN{izN|Mh|ryP NX\TNo5KW0GQR1XS
SKG-IIIa MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPuVmlKSzVyPUeuPFE5QTJizszN MmiwV2FPT0WU
HCE-T NXTDZYxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnGNFJKSzVyPUeuPFc4QDNizszN NY\P[XE6W0GQR1XS
Ca-Ski M3zrfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTdwOUmzPFMh|ryP MYfTRW5ITVJ?
COLO-684 M3iwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHXWGZKSzVyPUiuNFE5OThizszN M2j1eXNCVkeHUh?=
KYSE-70 NIrL[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmqzTWM2OD16LkC3O|I6KM7:TR?= NXXwflcyW0GQR1XS
TI-73 M176XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlW3TWM2OD16LkK1PFUyKM7:TR?= Mn31V2FPT0WU
BT-20 NF;McWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDoTWM2OD16LkK2NFUzKM7:TR?= MYPTRW5ITVJ?
MHH-ES-1 M3rWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vQemlEPTB;OD61NVg{PCEQvF2= MVLTRW5ITVJ?
TE-12 NYHWeFdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfoS5ZTUUN3ME24MlU6QTNzIN88US=> NEf1e3hUSU6JRWK=
YH-13 NGTyRZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRThwNkGwNFgh|ryP MmfyV2FPT0WU
SF126 M4HvTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zzd2lEPTB;OD64N|g3PSEQvF2= NFWzT|NUSU6JRWK=
J82 MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\oT2lEPTB;OD65NFA{QCEQvF2= MV\TRW5ITVJ?
RCC10RGB MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHkTWM2OD16Lkm5OVYyKM7:TR?= NGL4OYlUSU6JRWK=
SK-UT-1 M120Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljBTWM2OD17LkC0PVQ2KM7:TR?= MkfPV2FPT0WU
LB2241-RCC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVq2T4M3UUN3ME25MlE6OTN5IN88US=> MXHTRW5ITVJ?
LB996-RCC MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4W1fWlEPTB;OT6xPVg6KM7:TR?= NXS2bVdyW0GQR1XS
EPLC-272H MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfaVohwUUN3ME25MlM4PjV5IN88US=> M3TSVXNCVkeHUh?=
CTV-1 M{fqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLjRmZKSzVyPUmuOVY2OzJizszN M336U3NCVkeHUh?=
HSC-2 MnzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPVTWM2OD17LkW3OVUh|ryP M4jGSHNCVkeHUh?=
SK-MEL-28 NEntNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r5eWlEPTB;OT62NVg6OyEQvF2= NXHtem82W0GQR1XS
MMAC-SF NUK5OoJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\uc2tKSzVyPUmuOlg4PSEQvF2= NGnqOWRUSU6JRWK=
CP50-MEL-B MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DJSmlEPTB;OT63OVc5OiEQvF2= NV;qNZpoW0GQR1XS
HT-1080 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDWTWM2OD17Lke3O|M6KM7:TR?= MUXTRW5ITVJ?
HEC-1 M{GyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PLTGlEPTB;MUCuN|M2OiEQvF2= NI\wR2NUSU6JRWK=
AGS M1PzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zwc2lEPTB;MUCuN|c1KM7:TR?= NILRSpFUSU6JRWK=
GAMG MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3mxcWlEPTB;MUCuOVE3OiEQvF2= NIDBTGZUSU6JRWK=
SW48 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTkPINKSzVyPUGwMlUyQDlizszN NFu4bY5USU6JRWK=
U031 NHfNe|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLmTnRIUUN3ME2xNE42QTB6IN88US=> NV70OI13W0GQR1XS
OVCAR-5 M1fjUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ryZmlEPTB;MUCuOlQzQSEQvF2= M33iT3NCVkeHUh?=
SF295 M2jWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LJT2lEPTB;MUCuOlcxPCEQvF2= M2jmc3NCVkeHUh?=
BHT-101 NYi1eI91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFi5ZZFKSzVyPUGwMlcyPzdizszN MXfTRW5ITVJ?
VMRC-RCZ M3K2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3Gb4NwUUN3ME2xNU4{OjBzIN88US=> MlLFV2FPT0WU
ACHN M1;tOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUG4NmNLUUN3ME2xNU41OjFzIN88US=> MlvyV2FPT0WU
NCI-H526 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PqT2lEPTB;MUGuOVA1OyEQvF2= M4Dpc3NCVkeHUh?=
MN-60 M4r6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvDWlNlUUN3ME2xNU42OzlizszN M3nKT3NCVkeHUh?=
NCI-H2291 NVvHb|ZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XlZmlEPTB;MUGuOVQ3PiEQvF2= MnXBV2FPT0WU
SCC-25 M1iwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{[5bWlEPTB;MUGuO|U2PiEQvF2= MkWzV2FPT0WU
SK-MEL-2 MmrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfP[HhKSzVyPUGxMlc3OzdizszN NGn2fJpUSU6JRWK=
SN12C MlTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HLdGlEPTB;MUGuPVM2PSEQvF2= MVvTRW5ITVJ?
NCI-H69 NXz1SFkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLOU3dPUUN3ME2xNk41OjN2IN88US=> NF3BO2RUSU6JRWK=
ME-180 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnVfFZKSzVyPUGyMlcxPTRizszN MnzXV2FPT0WU
MC-IXC NX3QfGdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rndGlEPTB;MUKuO|UyQCEQvF2= NWrUU|BXW0GQR1XS
NCI-H2347 M2Lrbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnjS3hKSzVyPUGyMlc3OTRizszN Mn;EV2FPT0WU
M059J MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvsSGRKSzVyPUGyMlc4OjdizszN M4q1UHNCVkeHUh?=
A2058 NWrCcFR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDaSXAyUUN3ME2xNk45PjhzIN88US=> NIjVSIlUSU6JRWK=
VA-ES-BJ NXLS[mR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DtemlEPTB;MUKuPFc5PSEQvF2= NWnGUXFCW0GQR1XS
Ca9-22 M1jvW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTF{Lkm0OVEh|ryP MY\TRW5ITVJ?
KNS-42 M2D5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF{Lkm5PFQh|ryP MmTEV2FPT0WU
LoVo M3XNeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2W5S2lEPTB;MUOuNlMyOyEQvF2= M2fDfnNCVkeHUh?=
AM-38 NF\IeJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fhSWlEPTB;MUOuNlU3PiEQvF2= NH[3NFdUSU6JRWK=
NB5 NF;XNHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnaWXVKSzVyPUGzMlM4PTJizszN MnfRV2FPT0WU
L-363 NHr6Z5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\2OmlEPTB;MUOuOFA{OyEQvF2= NX6y[mhsW0GQR1XS
SK-MEL-30 M2LCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\DSWtRUUN3ME2xOE4xPjR3IN88US=> MULTRW5ITVJ?
NCI-H1563 M4\aS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L0PWlEPTB;MUSuOlA{QSEQvF2= M{\UPXNCVkeHUh?=
NCI-H2228 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTF2Lk[wO|ch|ryP Mne0V2FPT0WU
MFM-223 NXXBSYFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTF3LkG4NVMh|ryP NULRPGlrW0GQR1XS
LB831-BLC M2X6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlH3TWM2OD1zNT6yO|Y4KM7:TR?= M1rBdXNCVkeHUh?=
SW872 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF3LkOwPFYh|ryP NYO5TlFyW0GQR1XS
NCI-H522 M1W1VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPTO3IzUUN3ME2xOU4{OzB4IN88US=> MX3TRW5ITVJ?
EW-1 NEiwcotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XhZ2lEPTB;MUWuOVQ3OiEQvF2= NEfscWtUSU6JRWK=
HN MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTF3LkW5OFIh|ryP MX\TRW5ITVJ?
SW837 NYDTemlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkixTWM2OD1zNT63PFQ4KM7:TR?= NY\hRnU6W0GQR1XS
SCC-9 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDJTWM2OD1zNT64NVE1KM7:TR?= NHn5cphUSU6JRWK=
MKN7 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTJUIlEUUN3ME2xOU46PzN{IN88US=> MUjTRW5ITVJ?
KYSE-410 NX7IVI95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTF4LkW5NUDPxE1? NV\pXIIyW0GQR1XS
SK-N-DZ M3P0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVqwTlMzUUN3ME2xOk43OTF4IN88US=> MXzTRW5ITVJ?
COR-L105 NFPmOmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fPTmlEPTB;MU[uOlUzQCEQvF2= NULlWWEyW0GQR1XS
LB2518-MEL NFr4fWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;4UoxzUUN3ME2xOk45Ozh7IN88US=> M3HsO3NCVkeHUh?=
OVCAR-4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDwWZBZUUN3ME2xOk45QDZ{IN88US=> NIPwZ4NUSU6JRWK=
TK10 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HKTmlEPTB;MU[uPVQ4OyEQvF2= NELic4lUSU6JRWK=
KNS-62 NIP3ZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXW2cW9[UUN3ME2xOk46Pzd5IN88US=> MYfTRW5ITVJ?
RPMI-8866 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHBbXNKSzVyPUG3MlE4OzJizszN NH3JbXpUSU6JRWK=
HuP-T4 NGnDO4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTF5LkK0PVUh|ryP M1LJenNCVkeHUh?=
CGTH-W-1 NGiwNotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLJTWM2OD1zNz61NlE6KM7:TR?= MXnTRW5ITVJ?
T-24 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrLWWpKSzVyPUG3MlU{PDdizszN MUjTRW5ITVJ?
HT-3 M3nTTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEW5cY5KSzVyPUG3MlU6OTRizszN MlTFV2FPT0WU
KS-1 MlrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjyTnBKSzVyPUG3MlY4OyEQvF2= M3jNRXNCVkeHUh?=
NCI-H1792 NWC1O2F{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1f2dGlEPTB;MUeuO|k5KM7:TR?= NH7PbY1USU6JRWK=
ABC-1 NVfNVJN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn3b4hXUUN3ME2xO{45OTRzIN88US=> MnvDV2FPT0WU
BPH-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXP2OWl7UUN3ME2xPE4yPjh3IN88US=> MnTlV2FPT0WU
A431 NYX6OWRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH6zR|lKSzVyPUG4MlQyOjdizszN M1HBbXNCVkeHUh?=
T98G NIPFcIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTF6LkWxOVch|ryP MknqV2FPT0WU
BHY NYr0UG5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q1b2lEPTB;MUiuPFY6KM7:TR?= MV;TRW5ITVJ?
Capan-2 NIftfJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPSTWM2OD1zOD65NFc5KM7:TR?= M4LsTHNCVkeHUh?=
MDA-MB-175-VII MorRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljDTWM2OD1zOD65NlA6KM7:TR?= NU\3XlZ7W0GQR1XS
CAL-27 NF7ISYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInpfpRKSzVyPUG5MlA1QDdizszN NHvkVIpUSU6JRWK=
AsPC-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF7Lki2OVch|ryP NYTYcZZUW0GQR1XS
KU812 MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTF7Lkm1O|Mh|ryP NXfOe4k5W0GQR1XS
NCI-H441 MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXsWGVbUUN3ME2yNE4xODFizszN NYKxUnhyW0GQR1XS
Mewo MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f4PGlEPTB;MkCuNVI5QCEQvF2= NUPOe2lIW0GQR1XS
SK-MEL-24 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmKzTWM2OD1{MD6xOFc4KM7:TR?= NHnQZ25USU6JRWK=
NCI-H727 M1O0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3WwW2lEPTB;MkCuNlcxPCEQvF2= MmLvV2FPT0WU
EKVX NEDVUXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PYXGlEPTB;MkCuOlA3KM7:TR?= NYnpeHZpW0GQR1XS
RT-112 M33SNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\YNGlEPTB;MkCuOlEzOiEQvF2= NXzmcIw{W0GQR1XS
CAMA-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTJyLkm4NFMh|ryP NILNbHNUSU6JRWK=
SW900 NH2yXlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPCcY1mUUN3ME2yNU4xOTR7IN88US=> M3vQVHNCVkeHUh?=
NCI-H23 NYnVd5B5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTJzLkGyO|ch|ryP NX7FNW0zW0GQR1XS
SK-PN-DW M3LVVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPpXnNKSzVyPUKxMlE3PDlizszN NXLW[pVSW0GQR1XS
BB30-HNC M13KVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTJzLkK3OFUh|ryP M{D4bXNCVkeHUh?=
VM-CUB-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHntdVhKSzVyPUKxMlM2OzZizszN NF7sN2pUSU6JRWK=
IST-MEL1 Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1i4TGlEPTB;MkGuN|Y6OiEQvF2= NI\lbYdUSU6JRWK=
CTB-1 NY\JbHE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXW[XZwUUN3ME2yNU41PzV3IN88US=> MmfhV2FPT0WU
LCLC-103H MlLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfFTWM2OD1{Mj6xOVgzKM7:TR?= MX\TRW5ITVJ?
PANC-03-27 NITOeGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWq3SnJyUUN3ME2yNk42OTZ7IN88US=> MnTsV2FPT0WU
HTC-C3 MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPtTWM2OD1{Mj61OVU2KM7:TR?= M33zOnNCVkeHUh?=
TE-8 M1nF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moi5TWM2OD1{Mz6yOVY2KM7:TR?= NWnrWJdJW0GQR1XS
NCI-H292 M{fPemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknVTWM2OD1{NT6zOVM3KM7:TR?= NVTWbYx[W0GQR1XS
COLO-680N Mn3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHDSHVKSzVyPUK1MlY{OjlizszN MWTTRW5ITVJ?
KYSE-520 M1jzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrnSW5KSzVyPUK1MlY1PCEQvF2= MVvTRW5ITVJ?
NB10 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYT3O|NKUUN3ME2yOk4{OTF5IN88US=> MlK5V2FPT0WU
NCI-H661 MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rkdGlEPTB;Mk[uOFcyOyEQvF2= MVvTRW5ITVJ?
GMS-10 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfV[4pKSzVyPUK2Mlg3OzhizszN NUnPS2xGW0GQR1XS
NCI-H2122 MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJ4Lkm5PVgh|ryP M3\4WXNCVkeHUh?=
OVCAR-8 NXvaeZBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvHNo5yUUN3ME2yO{4xPjN6IN88US=> NGHROJhUSU6JRWK=
DJM-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXT3TGxOUUN3ME2yO{4yPDV2IN88US=> M1;DOXNCVkeHUh?=
UACC-893 NYXJRWFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vr[2lEPTB;MkeuPVg4QCEQvF2= MlXPV2FPT0WU
C8166 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHiTWM2OD1{OD62PVM5KM7:TR?= MnfiV2FPT0WU
NCI-H1693 M33Lbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3sTWM2OD1{OD62PVc2KM7:TR?= NWToVWM4W0GQR1XS
TYK-nu M1;4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTNyLkCzOFUh|ryP NHLpcGtUSU6JRWK=
SW1710 NGS3dJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTNyLkGyOkDPxE1? Mni4V2FPT0WU
A375 MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHqclJ1UUN3ME2zNE4{OjR|IN88US=> MUTTRW5ITVJ?
HMV-II M33IO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HzZ2lEPTB;M{GuN|U6OiEQvF2= M2K2THNCVkeHUh?=
NCI-H2087 M{\HW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjTSZh{UUN3ME2zNU43OzV{IN88US=> MVTTRW5ITVJ?
CAL-54 NYHwfVhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHiXplKSzVyPUOxMlczPDFizszN MX;TRW5ITVJ?
HCC70 M2PM[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGKxTmRKSzVyPUOyMlE{QDdizszN NV:0WFB5W0GQR1XS
ES1 M2LyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTN{LkOwOlIh|ryP MYDTRW5ITVJ?
NCI-H1355 NFnJbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXr[ItKSzVyPUOzMlIxPCEQvF2= M1\1bHNCVkeHUh?=
CFPAC-1 M3PHWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTN|LkKzN|Ih|ryP MofnV2FPT0WU
MKN28 NGPtSHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLhS4dKSzVyPUOzMlM5ODlizszN M4G4XnNCVkeHUh?=
HDLM-2 M4XqdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj2TnNKSzVyPUOzMlY6OzFizszN NE\YdZRUSU6JRWK=
PANC-10-05 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXW1XFF2UUN3ME2zOE4yODF2IN88US=> MWPTRW5ITVJ?
SAS MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjP[nBSUUN3ME2zOE41PTZ3IN88US=> M4LzPHNCVkeHUh?=
HCC1395 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfzTWM2OD1|ND63NVg3KM7:TR?= MlXUV2FPT0WU
8305C NH33XldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLxd4NKSzVyPUO1Mlg1OTVizszN MlvGV2FPT0WU
KM12 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPWb3JRUUN3ME2zOk44PTR5IN88US=> M2n5RXNCVkeHUh?=
SW1116 MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvQTWM2OD1|Nz61PVkzKM7:TR?= NFexOFRUSU6JRWK=
SK-MEL-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3qzbmlEPTB;M{iuN|M5QSEQvF2= MVjTRW5ITVJ?
HCC2218 NHvFeZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHiTWM2OD1|OD62OVE6KM7:TR?= NYrTToNkW0GQR1XS
T84 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVq4WJVpUUN3ME2zPE44PDB7IN88US=> MVPTRW5ITVJ?
ETK-1 M4O3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjrZYNKSzVyPUO5MlAzOiEQvF2= MYTTRW5ITVJ?
COLO-800 NWTYWlY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[wPGlEPTB;M{muN|g3QCEQvF2= MWnTRW5ITVJ?
CAL-12T NEi3S|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfiSFlKSzVyPUO5MlUzQDFizszN MVjTRW5ITVJ?
ACN NELWTnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjpbnBpUUN3ME20NE41QTFzIN88US=> MYTTRW5ITVJ?
SJSA-1 MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoG5TWM2OD12MT6xOVk3KM7:TR?= NYjQOYpmW0GQR1XS
PSN1 M3zBdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTRzLkG3OFkh|ryP NVnYTJR[W0GQR1XS
D-566MG NYP0SWVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPDS2R5UUN3ME20NU4zODh4IN88US=> NIX0V4NUSU6JRWK=
EGI-1 NWHBV2R1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nhXGlEPTB;NEKuOFI5KM7:TR?= MVHTRW5ITVJ?
A204 NGPj[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPSWot7UUN3ME20Nk43Ozh6IN88US=> M3n0R3NCVkeHUh?=
Saos-2 NXnFeGEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TtXWlEPTB;NEKuPFM3QSEQvF2= M4D2[XNCVkeHUh?=
SNU-C2B Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTR|Lk[4O|gh|ryP MlXPV2FPT0WU
HLE MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHOy[YJKSzVyPUS0MlA5PTZizszN NFnUbGJUSU6JRWK=
SW1463 NFi4UnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml61TWM2OD12ND65PVcyKM7:TR?= M3jaZnNCVkeHUh?=
DSH1 M1r4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonsTWM2OD12NT6wNFM{KM7:TR?= MWPTRW5ITVJ?
MCF7 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTR3LkWwOVEh|ryP Mo\IV2FPT0WU
K5 M{\ud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDWZ2dXUUN3ME20OU46PDB3IN88US=> M2HMfHNCVkeHUh?=
NCI-H358 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jO[WlEPTB;NEeuNlE2KM7:TR?= MU\TRW5ITVJ?
NCI-H2030 M2TEfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3m1NmlEPTB;NEeuNlM4PCEQvF2= NEDuTlNUSU6JRWK=
SW948 NVzY[pI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjwd2JKSzVyPUS3MlQ3PCEQvF2= NX\KVVMxW0GQR1XS
BALL-1 Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1joXWlEPTB;NEeuOlE3QCEQvF2= NID6ZmJUSU6JRWK=
TE-9 M4joeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPZZoFKSzVyPUS3Mlk2QDFizszN NUTobFBEW0GQR1XS
SK-N-FI MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\neZVYUUN3ME20PE4xOzV6IN88US=> MYHTRW5ITVJ?
KALS-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHXTWM2OD12OD6xNlg6KM7:TR?= NEfRcVBUSU6JRWK=
HO-1-N-1 Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnO3TWM2OD12OD63OFQ2KM7:TR?= NYDTUIREW0GQR1XS
NCI-H2452 MlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlL0TWM2OD12OT6xNVUzKM7:TR?= MkHSV2FPT0WU
OC-314 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTR7Lk[4N|Qh|ryP MXXTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo試験 When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]
臨床試験 ABT-263 is currently in Phase II clinical trial for the treatments of chronic lymphocytic leukemia.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Affinity determination Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.

細胞アッセイ:

[1]

細胞株 SCLC cell lines
濃度 0-1 μM
反応時間 48 hours
実験の流れ

Human tumor cell lines SCLC cell lines are maintained at 37 °C containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.

動物実験:

[1]

動物モデル C.B.-17 scid-bg or C.B.-17 scid mice
製剤 Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
投薬量 100 mg/kg/d
投与方法 Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download ABT-263 (Navitoclax) SDF
分子量 974.61
化学式

C47H55ClF3N5O6S3

CAS No. 923564-51-6
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 100 mg/mL (102.6 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 4-​[4-​[[2-​(4-​chlorophenyl)​-​5,​5-​dimethyl-​1-​cyclohexen-​1-​yl]​methyl]​-​1-​piperazinyl]​-​N-​[[4-​[[(1R)​-​3-​(4-​morpholinyl)​-​1-​[(phenylthio)​methyl]​propyl]​amino]​-​3-​[(trifluoromethyl)​sulfonyl]​phenyl]​sulfonyl]​-benzamide

カスタマーフィードバック (13)


Click to enlarge
Rating
Source , , J Clin Invest, 2014, 124(1): 117-28 . ABT-263 (Navitoclax) purchased from Selleck
Method Cell Viability Analysis
Cell Lines KP cells & A549 cells
Concentrations 300、500 nM
Incubation Time 96 h
Results KP mouse and A549 cells treated with a combination of ATN-224 and ABT-263 showed an increase in cell death compared with cells treated with ATN-224 alone.

Click to enlarge
Rating
Source , , Cell Death Differ, 2015, 10.1038/cdd.2015.73. ABT-263 (Navitoclax) purchased from Selleck
Method Cell Viability Analysis
Cell Lines NSC & Mcl-1 cells
Concentrations
Incubation Time 5 d
Results As seen with ABT-263, cells were largely resistant to compound alone but were extremely sensitive to combination with Mcl-1 silencing. In summary, the Bcl-xL inhibitors ABT-263 and WEHI-539 have an additive effect with Mcl-1 knockdown to reduce cell viabi眏Ỵ眐㠞眎膉癠 

Click to enlarge
Rating
Source Clin Cancer Res , 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Fluorescence polarization assay
Cell Lines
Concentrations 0.1-10 μmol/L
Incubation Time 4-12 h
Results To further characterize the nature of the binding of ABT-737 and ABT-263 to albumin, we used a fluorescence polarization assay.There are two main drug-binding sites on HSA: site 1 on subdomain IIA and site 2 on subdomain IIIA.Interestingly, ABT-263 displayed a markedly higher binding affinity to site 2 on HSA-III A than did ABT-737 (Fig. A). Whereas ABT-737 showed no binding to site 1, ABT-263 also bound to site 1 on HSA-IIA with an IC50 of 145 μmol/L (positive control phenylbutazone: 49 μmol/L; ref. 18; Fig. B) . These data show that ABT-263 has a higher albumin-binding capacity than does ABT-737, thus limiting the amount of free drug that is available to interact with the intended target, BCL2.

Click to enlarge
Rating
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Fluorescein-dextran release assay/western blot
Cell Lines CLL cells
Concentrations 0-5 μmol/L
Incubation Time 1-2.5 h
Results One possible explanation for the reduced potency of ABT-263 compared with ABT-737 could be due to the former being inherently less potent. To investigate this possibility we compared their activities in a model biochemical system, using liposomes loaded with fluorescein-conjugated 10 kD dextran.The BCL-XL-mediated inhibition of liposome permeabilization was reversed in an a lmost identical concentration-dependent manner by both ABT-263 and ABT-737 (Fig. A). These results showed that both ABT-263 and ABT-737 targe t antiapoptotic BCL-XL with similar efficiency in this model liposome system containing only BCL2 family members but devoid of extraneous proteins. Another explanation for the lower potency of ABT-263 could be a lower plasma membrane permeability.we investigated the potential of ABT-737 and ABT-263 to induce cytochromec release from permeabilized CLL cells(Fig. B). ABT-737 was clearly more potentin inducing cytochrome c release from permeabilized cells.Taken together these results indicate that the reduced potential of ABT-263 to induce apoptosis cannot be explained solely by either differential plasma membrane permeability or by a lower potency of ABT-263 compared with ABT-737 to inhibit antiapoptotic BCL2 family members.

Click to enlarge
Rating
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Mitochondrial membrane potential assay/Immunoprecipitation/electron microscopy/apoptosis assays
Cell Lines CLL cells/murine embryonic fibroblasts
Concentrations 10-100 nmol/L/0.3-30 μmol/L
Incubation Time 2-48 h
Results To gain in sight into the mechanism of ABT-263-induced cell death, we asked whether ABT-263 induced activation of apoptotic signaling pathways. ABT-263 induced a rapid cleavage of caspase-3 and loss of mitochondrial membrane potential, but was a gain less potent than ABT-737 ( Fig.A).To investigate the activity of both compounds at the level of BCL2 inhibition, we immunoprecipitated BCL2 upon drug treatment and measured the levels of BAK displaced by ABT-737 and ABT-263.BAK was shown to be associated with BCL2 (Fig. B). ABT-737 (10 or 100 nmol/L) efficiently d isplaced BAK from BCL2, whereas higher concentrations of ABT-263 (100 nmol /L) were required to induce release of BAK (Fig. B).ABT-263 (100 nmol/L) induced similar ultrastructural changes to ABT-737 (10 nmol/L), including condensed chromatin, rupture of the outer mitochondrial membrane, and loss of mitochondrial matrix d ensity (Fig. C).Finally, ABT-263-induced apoptosis was compl et ely inhibited in murine embryonic fibroblasts deficient for Bax and Bak (Fig. D), suggesting that ABT-263, like ABT-737 is a specific inhibitor of BCL2 proteins.

Click to enlarge
Rating
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Apoptosis assays
Cell Lines CLL cells
Concentrations 1-1000 nmol/L
Incubation Time 4 h
Results In our study we identify two factors that affect the efficacy of the ABT-263: high cell density and plasma protein binding. In leukemic patients, the high circulating cell densities might contribute to the resistance of CLL cells to ABT-263 that we observed in whole blood as compared with standard cell culture (Fig. B).We also describe that the ABT-263 is extensively bound to albumin and that in the presence of albumin higher drug concentrations are required for apoptosis induction (Fig. D)

Click to enlarge
Rating
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Apoptosis assays
Cell Lines CLL cells
Concentrations 1-1000 nmol/L
Incubation Time 4 h
Results We compared the in vitro efficacy of two very closely related BCL2 antagon ists, ABT-737 and ABT-263. A direct comparison of the susceptibility of freshly isolated CLL cells to ABT-737 and ABT-263 in RPMI supplemented with 10% FCS revealed that both compounds induced efficient apoptosis but ABT-737 was∼4-fold more potent.

Click to enlarge
Rating
Source PLoS One, 2011, 6, e21980. ABT-263 (Navitoclax) purchased from Selleck
Method Hoechst staining/western blot
Cell Lines LH86 cells/Huh7 cells
Concentrations 0–20 μM
Incubation Time 24 h
Results The higher dose of ABT-263 (10–20 μM) treatment for 24 h induced significant DNA fragmentation and caspase 9 or 3 cleavage activation in HCC cells, whereas lower concentrations of ABT-263 (0–2.5 μM) had no apoptotic toxicity to HCC cells. These results suggest that HCC cells are relatively resistant to low doses of ABT-263.

Click to enlarge
Rating
Source PLoS One, 2011, 6, e21980. ABT-263 (Navitoclax) purchased from Selleck
Method Western blot/Hoechst staining/Apoptosis assays
Cell Lines LH86 cells
Concentrations 1 μM
Incubation Time 1-6 h
Results As shown in Figure A, the combination treatment of HCC cells with ABT-263 (1 μM) and YM-155 (1μM) for up to 6 h has no effects on the expressions of either anti-apoptotic protein Bcl-xL or pro-apoptotic proteins including Bad, Bak, and Bax. However, as expected, the presence of YM-155 significantly decreased survivin protein expression (Figure B, left third lane). Co-treatment of cells with ABT-263 (1 μM) and YM-155 (1μM) induced an even greater decrease in survivin protein expression (Figure B, right two lanes) than that of YM-155 itself did. However, we indeed observed that ABT-263 single treatment for 3 h resulted in survivin increase (Figure B). To further determine survivin inhibition plays a critical role in sensitizing ABT-263 to induce apoptosis in HCC cells, we down-regulated survivin expression in HCC cells by siRNA duplexes targeted against human survivin mRNA, and then examined the expression of survivin by Western blotting (Figure C) and apoptotic events after ABT-263 treatments. The results demonstrated that ABT-263 induced significant apoptosis in the survivin siRNA-transfected cells, but not in siRNA Random-transfected (control) cells (Figure D, E, and F).

Click to enlarge
Rating
Source PLoS One, 2011, 6, e21980. ABT-263 (Navitoclax) purchased from Selleck
Method Western blot/Hoechst staining
Cell Lines LH86 cells
Concentrations 1-2.5 μM
Incubation Time 1-24 h
Results Treatment of cells with ABT-263 (1-2.5 μM) for 1 h could result in the increase of phosphorylated ERK (p-ERK) but not ERK (Figure A). On the other hand, as shown in Figure B, ABT-263 (1 μM) administration could result in survivin expression increase. Thus, in an attempt to know if ERK-survivin activation could protect cells against ABT-263 toxicity, cells were untreated or treated with ABT-263 (1 μM), PD98059 (50 μM), or pre-treated with PD98059 (50 μM) followed by ABT-263 (1 μM). As shown in Figure C and D, blocking ERK activation with specific inhibitor PD98059 enhanced ABT-263-indcued apoptosis in HCC cells. To further determine ERK anti-apoptotic effects on ABT-263 treated HCC cells, we knocked down ERK expression through siRNA mediated gene silencing (Figure E) and then administrated ABT-263. Similar results revealed that ERK depletion sensitized ABT-263-induced apoptosis (Figure F). These results suggest the activation of ERK-survivin may render cells to be resistant to low dose ABT-263-induced apoptosis.

Click to enlarge
Rating
Source Biochem Biophys Res Commun, 2011, 408(2), 344-9. ABT-263 (Navitoclax) purchased from Selleck
Method Flow cytometry
Cell Lines MDCKII wild type cells/MDR1 cells
Concentrations 50 nM
Incubation Time 24 h
Results MDCKII cells transfected with MDR1 showed significantly less apoptosis inducedby ABT-737 (Fig. C) and ABT-263 (Fig. D) than wild type cells.

Click to enlarge
Rating
Source ABT-263 (Navitoclax) purchased from Selleck
Method Western Blotting/Co-Immunoprecipitation / Cell Death Experiments
Cell Lines Arf -null p185+ cells/ p185+ Arf-/- cells
Concentrations 0-1000nM
Incubation Time 24 h
Results As the navitoclax dose increased the amount of BCL-2 and BCL-X L immunoprecipitating with BIM decreased and there was a corresponding increase in MCL-1 protein associated with BIM (Fig. B). These data indicated that navitoclax displaced BIM from BCL-2 and BCL-XL and suggests that the liberated BIM could then interact with MCL-1 (Fig. B). As the navitoclax was increased we observed potentiation of the TKIs indicating a synergistic effect of combining navitoclax and TKI treatment (Fig. E&F).

Click to enlarge
Rating
Source ABT-263 (Navitoclax) purchased from Selleck
Method Western Blotting/Co-Immunoprecipitation / Cell Death Experiments
Cell Lines OP-1 Ph+ B-ALL cells/TOM1 Ph+ B-ALL cells/BV173 Ph+CML cells
Concentrations 0-60 nM
Incubation Time 24 h
Results As navitoclax was increased in the cultures we observed a potentiation of the TKIs to induce apoptosis. These data indicate that like our bservations in mouse BCR-ABL cell lines, combining TKIs and navitoclax in human Ph+ cell lines can also lead to enhanced activity. While MCL-1 expression is most overtly decreased in response to TKI treatment, it is possible that combining TKI and navitoclax may effect targets other than MCL-1 leading to cell death. These data suggest that combining TKIs and navitoclax may be effective in treating human Ph+ leukemia.

文献中の引用 (35)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related Bcl-2 阻害剤

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Kiof < 0.010 nM.

    Features:Re-engineered version of ABT-263 (Navitoclax).

  • ABT-737

    ABT-737は、Bcl-xL、Bcl-2とBcl-wのBH3模倣の阻害剤で、EC50 がそれぞれ78.7 nM、30.3 nM 、197.8 nMになる。

  • UMI-77

    UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.

  • Obatoclax Mesylate (GX15-070)

    Obatoclax Mesylate (GX15-070)は Bcl-2 を抑制して、 Kiが0.22 μMになる.

    Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

  • TW-37

    TW-37は、組み換え型Bcl-2(Bcl-xLとMcl-1)への新しい非ペプチド阻害剤で、Ki がそれぞれ 0.29 μM、1.11 μM、0.26 μMです。

  • Sabutoclax

    Sabutoclax is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.

  • AT101

    AT-101は、反アポトーシスのBcl-2 の強力な阻害剤であることを知られて、模倣のBH3家族です。

最近チェックしたアイテム

Tags: ABT-263 (Navitoclax)を買う | ABT-263 (Navitoclax)供給者 | ABT-263 (Navitoclax)を購入する | ABT-263 (Navitoclax)費用 | ABT-263 (Navitoclax)生産者 | オーダーABT-263 (Navitoclax) | ABT-263 (Navitoclax)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ